Loading, please wait ...


News Analytics

leopharma.
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum® in the European Union) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited.
Google

Subject Matter

  • Healthcare 100.00%
    • Hospitals, doctors and medical care 100.00%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions